Coalition Against Major Diseases Introduces the First Combined Pharmaceutical Trial Data on Neuro-degenerative Diseases A new database of more than 4,000 Alzheimer’s disease patients who have participated in 11 industry-sponsored clinical trial
Critical Path Institute’s Predictive Safety Testing Consortium Announces First-Ever Qualification Decision by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). For the first time, new biomarker tests to detect drug-induced kidney injury have been accepted by the Japanese Pharmaceuticals an
March 23, 2010 First Annual Patient-Reported Outcome Consortium Workshop March 23, 2010 Sheraton Silver Spring Hotel 8777 Georgia Avenue – Silver Spring, MD 20910 SPONSORED BY: Critical Path Instit
Critical Path Institute’s Predictive Safety Testing Consortium Announces Special Issue of Nature Biotechnology Dedicated to Newly Qualified Kidney Safety Biomarkers A special May 10, 2010 issue of Nature Biotechnology (NBT) includes ten scientific publications from Critical Path Institute’
Kidney injury Molecule-1 Outperforms Traditional Biomarkers of Kidney Injury in Preclinical Biomarker Qualification Studies
A Panel of Urinary Biomarkers to Monitor Reversibility of Renal Injury and a Serum Marker with Improved Potential to Assess Renal Function
October 5, 2010 Renal Biomarker Qualification Submission: A Dialog Between the FDA-EMEA and Predictive Safety Testing Consortium